A multinational phase II trial of bevacizumab with low-dose interferon- 2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial

(2011) Sylvie Négrier et al.   LANCET ONCOLOGY

Overall survival in patients with metastatic renal cell carcinoma initially treated with bevacizumab plus interferon-α2a and subsequent therapy with tyrosine kinase inhibitors: a retrospective analysis of the phase III AVOREN trial

(2010) Sergio Bracarda et al.   BJU INTERNATIONAL

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

(2010) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Bevacizumab Plus Interferon Alfa Versus Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: Final Results of CALGB 90206

(2010) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

(2010) Cora N. Sternberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Durable Remission of Metastatic Renal Cell Carcinoma With Gemcitabine and Capecitabine After Failure of Targeted Therapy

(2010) Stephen L. Richey et al.   JOURNAL OF CLINICAL ONCOLOGY

Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients

(2010) S. Wu et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management

(2009) Hassane Izzedine et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma

(2008) B. Melichar et al.   ANNALS OF ONCOLOGY

Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206

(2008) Brian I. Rini et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase II Trial of Gemcitabine Plus Capecitabine for Metastatic Renal Cell Cancer Previously Treated With Immunotherapy and Targeted Agents

(2008) Nizar M. Tannir et al.   JOURNAL OF UROLOGY